Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01345318
Registration number
NCT01345318
Ethics application status
Date submitted
28/04/2011
Date registered
2/05/2011
Date last updated
12/01/2024
Titles & IDs
Public title
B0151005 Open-Label Extension Study
Query!
Scientific title
A Multicenter Open-label Extension Study For Subjects Who Participated In Study B0151003 (Andante Ii)
Query!
Secondary ID [1]
0
0
2011-000722-30
Query!
Secondary ID [2]
0
0
B0151005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ANDANTE II
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Crohn's Disease
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Inflammatory bowel disease
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Crohn's disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - PF-04236921
Other interventions - PF-04236921
Experimental: Open-label Treatment -
Other interventions: PF-04236921
Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
Other interventions: PF-04236921
Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs
Query!
Assessment method [1]
0
0
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Lack of efficacy was reported as an AE when it was associated with a SAE. An AE was considered treatment emergent if it started for the first time in a participant on or after the first day of active treatment, or the event started before the first day of active treatment but increased in severity during active treatment. AEs included both SAEs and non-serious AEs.
Query!
Timepoint [1]
0
0
Baseline up to Week 48
Query!
Primary outcome [2]
0
0
Percentage of Participants Developing Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)
Query!
Assessment method [2]
0
0
Samples were analyzed using the semi-quantitative electrochemiluminescent (ECL) immunoassay method, a validated analytical method in compliance with sponsor's standard operating procedures. ADA positive is defined as ADA titer greater than or equal to (>=) 4.32. Any positive ADA sample was further tested for NAbs.
Query!
Timepoint [2]
0
0
At Baseline and Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72 and 76.
Query!
Eligibility
Key inclusion criteria
- Subjects previously enrolled in study B0151003 and completed the blinded 84 day (12
week) induction period.
- Subjects who are willing and able to comply with scheduled visits, treatment plan,
laboratory tests, and other study procedures.
- Women of childbearing potential, who have sexual intercourse with a non surgically
sterilized male partner, must agree and commit to the use highly effective methods of
birth control from signing of the ICD through 26 weeks after the Final Study
Evaluation or for 62 weeks from the last dose of investigational product for any
subject who terminates early from this study.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects that have completed Day 84 (Week 12) of study B0151003, and experienced
serious event(s) related to the investigational product, an unstable medical
condition, or any other reason, in the opinion of the investigator, would preclude
entry or inclusion in this study.
- Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate entry into this study.
- Received any prohibited treatment during study B0151003 that, in the opinion of the
investigator, compromised the safety or efficacy of this study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
191
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [2]
0
0
Royal Brisbane and Women's Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Mater Health Services - South Brisbane
Query!
Recruitment hospital [4]
0
0
Eastern Health, Box Hill Hospital - Box Hill
Query!
Recruitment hospital [5]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [6]
0
0
St. Vincent's Hospital - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
4029 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [5]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [6]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oklahoma
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Bruxelles
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Leuven
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Roeselare
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
PR
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
RJ
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
SP
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Alberta
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Ontario
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Quebec
Query!
Country [26]
0
0
Czechia
Query!
State/province [26]
0
0
Hradec Kralove
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Olomouc
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Praha 10
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Praha 4
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Usti nad Labem
Query!
Country [31]
0
0
Denmark
Query!
State/province [31]
0
0
Aarhus C
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Herlev
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Hilleroed
Query!
Country [34]
0
0
Denmark
Query!
State/province [34]
0
0
Hvidovre
Query!
Country [35]
0
0
Denmark
Query!
State/province [35]
0
0
Koebenhavn NV
Query!
Country [36]
0
0
Denmark
Query!
State/province [36]
0
0
Koebenhavn
Query!
Country [37]
0
0
Denmark
Query!
State/province [37]
0
0
Koege
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Cedex 12
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Lille Cedex
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Niedersachsen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Hamburg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Kiel
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Minden
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Debrecen
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Szeged
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Szekszard
Query!
Country [48]
0
0
Ireland
Query!
State/province [48]
0
0
Dublin
Query!
Country [49]
0
0
Ireland
Query!
State/province [49]
0
0
Galway
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Jerusalem
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Haifa
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Kfar Saba
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Petah Tikva
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Aviv
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Milano
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Padova
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Roma
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Rome
Query!
Country [59]
0
0
New Zealand
Query!
State/province [59]
0
0
Auckland
Query!
Country [60]
0
0
New Zealand
Query!
State/province [60]
0
0
Hamilton
Query!
Country [61]
0
0
Switzerland
Query!
State/province [61]
0
0
Zuerich
Query!
Country [62]
0
0
United Kingdom
Query!
State/province [62]
0
0
Cambridge
Query!
Country [63]
0
0
United Kingdom
Query!
State/province [63]
0
0
Glasgow
Query!
Country [64]
0
0
United Kingdom
Query!
State/province [64]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a multi-center Phase 2, open label, safety extension study in subjects with moderate
to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will
have completed the 12-week induction period of study B0151003 and will be enrolled as either
responders or non responders.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01345318
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01345318
Download to PDF